InsiderTrades.com logo

ENTX Insider Trading

Insider Ownership Percentage: 10.57%
Insider Buying (Last 12 Months): $92,530.00
Insider Selling (Last 12 Months): $0.00

Entera Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Entera Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entera Bio Share Price & Price History

Current Price: $3.31
Price Change: ▲ Price Increase of +0.075 (2.32%)
As of 08/24/2026 10:18 AM ET

This chart shows the closing price history over time for ENTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Entera Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2026Geno J GermanoDirectorBuy20,000$1.30$26,000.0040,000View SEC Filing Icon  
3/5/2026Sean EllisDirectorBuy10,000$1.23$12,300.00188,098View SEC Filing Icon  
2/9/2026Sean EllisDirectorBuy18,000$1.24$22,320.00178,098View SEC Filing Icon  
2/9/2026Steven D RubinDirectorBuy10,000$1.20$12,000.0010,000View SEC Filing Icon  
12/29/2025Miranda Jayne ToledanoCEOBuy11,000$1.81$19,910.00426,575View SEC Filing Icon  
1/12/2024Haya TaitelDirectorBuy9,500$0.99$9,405.0035,115View SEC Filing Icon  
1/10/2024Haya TaitelDirectorBuy7,615$0.77$5,863.5525,615View SEC Filing Icon  
12/22/2023Miranda Jayne ToledanoCEOBuy23,952$0.71$17,005.92110,752View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Entera Bio (NASDAQ:ENTX)

14.11% of Entera Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Entera Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/22/2026Seven Fleet Capital Management LP191,354$0.34M0.1%-6.9%0.111%Search for SEC Filing on Google Icon
6/4/2026Seven Fleet Capital Management LP205,542$0.23M0.1%+51.9%0.418%Search for SEC Filing on Google Icon
5/14/2026Renaissance Technologies LLC473,442$0.53M0.0%+338.4%0.962%Search for SEC Filing on Google Icon
2/26/2026Seven Fleet Capital Management LP135,318$0.26M0.2%N/A0.295%Search for SEC Filing on Google Icon
2/18/2026Superstring Capital Management LP17,142$33K0.0%N/A0.037%Search for SEC Filing on Google Icon
2/17/2026Schonfeld Strategic Advisors LLC596,585$1.16M0.0%+5.2%1.301%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC74,064$0.14M0.0%+142.6%0.162%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC108,001$0.21M0.0%+22.2%0.236%Search for SEC Filing on Google Icon
2/6/2026HighTower Advisors LLC43,140$84K0.0%+137.8%0.094%Search for SEC Filing on Google Icon
11/17/2025Parkman Healthcare Partners LLC280,822$0.54M0.1%-21.1%0.615%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC39,978$77K0.0%+243.0%0.088%Search for SEC Filing on Google Icon
11/14/2025Schonfeld Strategic Advisors LLC566,956$1.09M0.0%-6.2%1.242%Search for SEC Filing on Google Icon
8/15/2025Bank of America Corp DE23,430$45K0.0%-24.4%0.051%Search for SEC Filing on Google Icon
8/1/2025Bessemer Group Inc.140,843$0.27M0.0%N/A0.310%Search for SEC Filing on Google Icon
5/16/2025Parkman Healthcare Partners LLC439,632$0.75M0.1%+6.3%0.968%Search for SEC Filing on Google Icon
5/13/2025HighTower Advisors LLC18,140$31K0.0%+53.3%0.040%Search for SEC Filing on Google Icon
2/18/2025Knoll Capital Management LLC5,881,879$12.47M8.0%+51.5%16.439%Search for SEC Filing on Google Icon
2/14/2025Schonfeld Strategic Advisors LLC632,311$1.34M0.0%-2.5%1.767%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp212,483$0.45M0.0%N/A0.594%Search for SEC Filing on Google Icon
1/22/2025Perigon Wealth Management LLC145,843$0.33M0.0%N/A0.408%Search for SEC Filing on Google Icon
11/15/2024Parkman Healthcare Partners LLC411,076$0.78M0.1%+2.4%1.149%Search for SEC Filing on Google Icon
11/6/2024Signature Estate & Investment Advisors LLC47,328$90K0.0%N/A0.132%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC57,600$0.11M0.0%-23.1%0.161%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC22,040$37K0.0%N/A0.000%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.295,966$0.22M0.0%-85.8%1.028%Search for SEC Filing on Google Icon
11/14/2022RA Capital Management L.P.2,082,372$2.17M0.0%-11.5%7.229%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Entera Bio logo
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio

Today's Range

Now: $3.31
Low: $3.20
High: $3.33

50 Day Range

MA: $2.20
Low: $1.18
High: $3.92

52 Week Range

Now: $3.31
Low: $0.91
High: $4.20

Volume

38,274 shs

Average Volume

1,122,574 shs

Market Capitalization

$572.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Who are the company insiders with the largest holdings of Entera Bio?

Entera Bio's top insider shareholders include:
  1. Miranda Jayne Toledano (CEO)
  2. Sean Ellis (Director)
  3. Geno J Germano (Director)
  4. Haya Taitel (Director)
  5. Steven D Rubin (Director)
  6. Ramesh Ratan (CFO)
  7. Ron Mayron (Director)
  8. Yonatan Malca (Director)
Learn More about top insider investors at Entera Bio.

Who are the major institutional investors of Entera Bio?

Entera Bio's top institutional investors include:
  1. Seven Fleet Capital Management LP — 0.11%
Learn More about top institutional investors of Entera Bio stock.

Which major investors are selling Entera Bio stock?

Within the last quarter, ENTX stock was sold by these institutional investors:
  1. Seven Fleet Capital Management LP

Entera Bio Active Insiders

Miranda Jayne Toledano
Miranda Jayne Toledano (Age 49)
CEO
Ramesh Ratan
CFO
Yonatan Malca
Director
Ron Mayron
Ron Mayron
Director
Geno J Germano
Geno J Germano
Director
1 recent trades
Sean Ellis
Director
1 recent trades